New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts: GAO-07-49

Aronovitz, Leslie G.
December 2006
GAO Reports;12/19/2006, p1
Government Document
Drug development is complex and costly, requiring the testing of numerous chemical compounds for their potential to treat disease. Before a new drug can be marketed in the United States, a new drug application (NDA), which includes scientific and clinical data, must be approved by the Food and Drug Administration (FDA). Recent scientific advances have raised expectations that an increasing number of new and innovative drugs would soon be developed to more effectively prevent, treat, and cure serious illnesses. However, industry analysts and the FDA have reported that new drug development, and in particular, development of new molecular entities (NMEs)--potentially innovative drugs containing ingredients that have never been marketed in the United States--has become stagnant. GAO was asked to provide information on (1) trends in the pharmaceutical industry's reported research and development expenses as well as trends in the number of NDAs submitted to, and approved by, FDA; and (2) experts' views on factors accounting for these trends and their suggestions for expediting and enhancing drug development. GAO analyzed data from FDA on all 1,264 NDAs submitted to the agency from 1993 through 2004. GAO also convened a panel of experts and interviewed other drug development experts and analysts to identify factors affecting, and suggestions for enhancing, drug development. Although the pharmaceutical industry reported substantial increases in annual research and development costs, the number of NDAs submitted to, and approved by, FDA has not been commensurate with these investments. From 1993 through 2004, industry reported annual inflation-adjusted research and development expenses steadily increased from nearly $16 billion to nearly $40 billion--a 147 percent increase. In contrast, the number of NDAs submitted annually to FDA increased at a slower rate--38 percent over this period. Similarly, the number of NDAs submitted to FDA for NMEs increased by only 7 percent over this period. FDA approved most NDA applications--76 percent overall, but the numbers of NDAs and NDAs for NMEs it approved annually have generally been declining since 1996. According to experts, several factors have hampered drug development. These include limitations on the scientific understanding of how to translate research discoveries into safe and effective drugs, business decisions by the pharmaceutical industry, uncertainty regarding regulatory standards for determining whether a drug should be approved, and certain intellectual property protections. These factors have been cited as affecting the number of drugs developed, the cost and length of the drug development process, as well as the types of drugs being produced. To address these issues, experts offered suggestions including increasing the number of scientists who can translate drug discoveries into effective new medicines and allowing conditional approval of certain drugs based on shorter clinical...


Related Articles

  • Left Out. Clinton, Patrick // Pharmaceutical Executive;Jan2007, Vol. 27 Issue 1, p16 

    The author reflects on the issue about the cost of developing new drugs in the U.S. He states that a report from the Government Accountability Office piles up a list of reasons why research and development is expensive. He stresses that these include failure to understand how to translate basic...

  • Pressure Mounts to Streamline Trials. Wechsler, Jill // Applied Clinical Trials;Mar2007, Vol. 16 Issue 3, p24 

    The article focuses on the declining productivity of the pharmaceutical research enterprises in the U.S., and the increasing cost of drug development. According to the Government Accountability Office, research and development spending has increased from $40 billion in 2004 to $60 billion in...

  • Drug Safety: FDA Needs to Further Address Shortcomings in Its Postmarket Decision-making Process: GAO-07-599T.  // GAO Reports;3/22/2007, p1 

    GAO was asked to testify on the effectiveness of the Food and Drug Administration's (FDA) postmarket decision-making process. This testimony is based on Drug Safety: Improvement Needed in FDA's Postmarket Decision-making and Oversight Process, GAO-06-402 (March 31, 2006). The report focused on...

  • Struggling with Shortages. Wechsler, Jill // Pharmaceutical Executive;Nov2011, Vol. 31 Issue 11, p12 

    The article focuses on the drug shortage crisis in the U.S. during 2010 and 2011, which is mainly due to supply chain problems in the pharmaceutical industry. The U.S. Food & Drug Administration (FDA) recorded 178 drug shortages in the U.S. in 2010, up from 157 in 2009; and three-fourths of the...

  • Foreign Inspections. Mitka, Mike // JAMA: Journal of the American Medical Association;12/10/2008, Vol. 300 Issue 22, p2599 

    The U.S. Government Accountability Office (GAO) has found inspection by the U.S. Food and Drug Administration (FDA) of foreign manufacturing facilities that produce pharmaceuticals to be lacking. The GAO reports that the FDA databases contain inaccurate and possibly incomplete information on...

  • GAO: Drug company research costs have not led to more treatments. Arias, Donya C. // Nation's Health;Feb2007, Vol. 37 Issue 1, p18 

    The article discusses the findings of the "New Drug Development: Science, Business, Regulatory and Intellectual Property Issues Cited as Hampering Drug Development Efforts" report issued by the U.S. Government Accountability Office. Findings stated that higher research expenditures have not...

  • Pharma: What's in a Name? E. B. // Information Today;Sep2011, Vol. 28 Issue 8, p13 

    The article focuses on the risk to public health and safety posed by the penmanship of a doctor, based on the Thomson CompuMark report "Pharmaceutical Trademarks: How to Survive the Name Game-New Challenges and Opportunities for Pharmaceutical Companies," by Jeroen Lallemand released in May 2011.

  • India Looks to Ethical Drugs. Scott, Alex // Chemical Week;6/15/2005, Vol. 167 Issue 20, p27 

    Reports on the efforts of pharmaceutical manufacturing sector in India to comply with patent laws for the protection of intellectual property. Approach used by Indian custom pharmaceutical manufacturers in the production of generic drugs; Comparison between the development costs of a drug in...

  • Challenges of Scale-up and Commercialization. Kulp, Christopher // Pharmaceutical Processing;Sep2014, Vol. 29 Issue 7, p30 

    The article discusses the challenges associated with scale-up and commercialization of new drugs and in drug devlopment, focusing on project manager model as the best outsourcing option. Topics include the current Good Manufacturing Practices (cGMP) of the U.S. Food and Drug Administration...


Read the Article

Other Topics